However, the latest clinical study by Luo J, Makhnin A et al. pointed out that in the drug-resistant EGFR-mutant LUAD that had previously appeared with a tyrosine kinase inhibitor, the addition of trametinib could not reverse the sensitivity of the tumor to the drug (Luo et al., 2021), which means that TMPO-AS1 may be a potential target to solve this problem, which is worthy of further study. The gene discussed is EGFR; the disease is neoplasm.